140P Patient-reported outcomes (PRO) following sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: A randomized, double-blind, phase III study (Orient-12). (December 2022) - Zhou, C.; Gao, G.; Fan, Y.; Liu, L.; Zhang, L.; Cang, S.; Zhou, J.; Li, B.; Yang, Y.; Li, J.